Bristol Myers Opdivo gets EMA panel backing for expanded use in lung cancer
hapabapa/iStock Editorial via Getty Images
- A committee of the European Medicines Agency (EMA) recommended the expanded approval of Bristol Myers Squibb's (NYSE:BMY) Opdivo as a neoadjuvant treatment for certain patients with non-small cell lung cancer (NSCLC).
- The EMA's Committee for Medicinal Products for Human Use (CHMP) noted that Opdivo (nivolumab) in combination with platinum-based chemotherapy is indicated as an neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumors have PD-L1 expression ≥ 1%.
- The drug is already approved to treat several types of cancer.
- The European Commission (EC), which generally follows the opinion of the CHMP, will make final decision on the change to the marketing authorization of the drug.
More on Bristol Myers
- Bristol-Myers Squibb: Attractive Entry As New Products Sales Accelerate
- Bristol-Myers Squibb Q1 Earnings: Is CEO Caforio's Sudden Departure A Concern?